More on health data

Readers who were interested in my earlier post on Overdiagnosed will enjoy reading today's New York Times Op-Ed by two of that book's authors, Steven Woloshin and Lisa M. Schwartz. In it, they argue that federal regulators should require drug manufacturers to provide understandable information about effectiveness and side effects on outside packaging. If we can do it for sunscreen, they argue, why not for prescription drugs?

Here's a screenshot of the accompanying graphic using Abilify, an anti-psychotic, as an example: